Geneos Wealth Management Inc. Boosts Position in Invesco Pharmaceuticals ETF (NYSEARCA:PJP)

Geneos Wealth Management Inc. raised its holdings in shares of Invesco Pharmaceuticals ETF (NYSEARCA:PJP) by 91.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,050 shares of the company’s stock after acquiring an additional 980 shares during the period. Geneos Wealth Management Inc. owned approximately 0.06% of Invesco Pharmaceuticals ETF worth $164,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Principal Securities Inc. purchased a new position in Invesco Pharmaceuticals ETF during the fourth quarter valued at approximately $31,000. ICA Group Wealth Management LLC purchased a new position in shares of Invesco Pharmaceuticals ETF during the 4th quarter valued at approximately $37,000. Kraft Davis & Associates LLC acquired a new position in shares of Invesco Pharmaceuticals ETF in the 4th quarter valued at $277,000. Modera Wealth Management LLC acquired a new position in shares of Invesco Pharmaceuticals ETF in the 3rd quarter valued at $538,000. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Invesco Pharmaceuticals ETF by 22.9% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 7,729 shares of the company’s stock worth $620,000 after buying an additional 1,438 shares in the last quarter.

Invesco Pharmaceuticals ETF Stock Performance

PJP opened at $83.97 on Friday. The company has a fifty day moving average of $80.81 and a two-hundred day moving average of $78.53. The stock has a market capitalization of $284.67 million, a price-to-earnings ratio of 21.48 and a beta of 0.61. Invesco Pharmaceuticals ETF has a fifty-two week low of $67.75 and a fifty-two week high of $84.03.

Invesco Pharmaceuticals ETF Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.